

MARKET CONSULTATION SOLACTIVE UNITED STATES BIOTECHNOLOGY INDEX

05 April 2023



Content of the Market Consultation

Solactive AG has decided to conduct a Market Consultation with regard to changing the Index Methodology of the following Indices (the 'Indices'):

| NAME | RIC | ISIN |
|---|-----------|--------------|
| Solactive United States Biotechnology Index PR | .SOLUSBTP | DE000SLOH894 |
| Solactive United States Biotechnology Index NTR | .SOLUSBTN | DE000SLOH9A7 |
| Solactive United States Biotechnology Index TR | .SOLUSBTT | DE000SLOH9B5 |

Rationale for the Market Consultation

The Indices aim to represent US listed securities that have business operations in the biotechnology industry. This includes companies that are headquartered in and outside of the United States. Solactive would like to suggest decreasing the exposure to companies that are not headquartered in the United States.

Therefore, Solactive proposes to implement a single security cap of 4% on American depositary receipt.

Proposed Changes to the Index Guideline

The following Methodology changes are proposed in the following points of the Index Guideline (ordered in accordance with the numbering of the affected sections):

Section 2.3 Weighting of the Index Components

From (old version):

"[...]

- 1) The individual maximum weight of the top four INDEX COMPONENTS by FREE FLOAT MARKET CAPITALIZATION is at 8%.
- 2) All other INDEX COMPONENTS are capped at 4%

"[...]"

To (new version):



"[...]

- 1) The individual maximum weight of each American depositary receipt is at 4%.
- 2) The individual maximum weight of the top four INDEX COMPONENTS by FREE FLOAT MARKET CAPITALIZATION is at 8%.
- 3) All other INDEX COMPONENTS are capped at 4%


[...]"

Feedback on the proposed changes

If you would like to share your thoughts with Solactive, please use this consultation form and provide us with your personal details and those of your organization.

| | |
|-----------------------|--|
| Name | |
| Function | |
| Organization | |
| Email | |
| Phone | |
| Confidentiality (Y/N) | |

Solactive is inviting all stakeholders and interested third parties to evaluate the proposed changes to the Methodology for the Solactive United States Biotechnology Index and welcomes any feedback on how this may affect and/or improve their use of Solactive indices.



Consultation Procedure

Stakeholders and third parties who are interested in participating in this Market Consultation, are invited to respond until *May 19th 2023 (cob)*.

Subject to feedback received on this Market Consultation, the changes mentioned above are intended to become effective on *May 30th 2023*.

Please send your feedback via email to marketconsultation@solactive.com, specifying "Market Consultation I Solactive United States Biotechnology Index" as the subject of the email, or

via postal mail to: Solactive AG
Platz der Einheit 1
60327 Frankfurt am Main
Germany

Should you have any additional questions regarding the consultative question in particular, please do not hesitate to contact us via above email address.

CONTACT

Solactive AG

German Index Engineering

Platz der Einheit 1

60327 Frankfurt am Main

Germany

Tel.: +49 (0) 69 719 160 00

Fax: +49 (0) 69 719 160 25

Email: info@solactive.com

Website: www.solactive.com

© Solactive AG